Hyperion DeFi, Inc. Overview
Pro stress-test →Hyperion DeFi is the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, focused on providing shareholders with simplified access to one of the fastest-growing, highest revenue-generating blockchains in the world. The company continues to develop its proprietary Optejet User Filled Device, a medical dispensing platform for topical ophthalmic liquids designed to improve ease of use and patient compliance.
Strategic Profile
Pro stress-test →The company transitioned from its former identity as Eyenovia, Inc., changing its name to Hyperion DeFi in July 2025. Its core strategy centers on a cryptocurrency treasury reserve strategy with HYPE tokens native to the Hyperliquid blockchain protocol, with a validator node launched through Kinetiq collaboration for staking and yield generation. Recent developments include an institutional volatility income vault built on Rysk protocol using HYPE liquid staking tokens and stablecoins for on-chain options strategies.
Competitive Landscape
Pro stress-test →Hyperion DeFi operates as the first publicly-listed U.S. company with a strategic HYPE treasury, differentiating itself in the nascent intersection of public equities and blockchain infrastructure. Other crypto-focused public companies pursue similar treasury strategies, but Hyperion's dual focus on DeFi yield generation and traditional ophthalmic device development creates a hybrid business model with limited direct competitors. The company faces competitive pressures from established DeFi protocols and other crypto treasury strategies seeking institutional capital.
Industry Context
Hyperion DeFi, Inc. operates in Decentralized Finance (DeFi) & Blockchain Infrastructure / Ophthalmic Medical Devices.
Key facts
Founded: 2014 · Headquarters: Laguna Hills, California, USA · Revenue: $0.30M (Q3 2025)